Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
73.00
+0.35 (0.48%)
Apr 14, 2026, 1:07 PM EDT - Market open
Tarsus Pharmaceuticals Revenue
In the year 2025, Tarsus Pharmaceuticals had annual revenue of $451.36M with 146.71% growth. Tarsus Pharmaceuticals had revenue of $151.67M in the quarter ending December 31, 2025, with 128.39% growth.
Revenue (ttm)
$451.36M
Revenue Growth
+146.71%
P/S Ratio
6.85
Revenue / Employee
$1,219,892
Employees
370
Market Cap
3.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 451.36M | 268.41M | 146.71% |
| Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
| Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
| Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
| Dec 31, 2021 | 57.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.03B |
| Catalyst Pharmaceuticals | 588.99M |
| Arcutis Biotherapeutics | 376.07M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Tango Therapeutics | 62.38M |
| Alumis | 24.05M |
TARS News
- 14 days ago - Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease - GlobeNewsWire
- 22 days ago - TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - GlobeNewsWire
- 6 weeks ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 - GlobeNewsWire
- 5 months ago - Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewsWire
- 5 months ago - Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 8 months ago - Top 2 Health Care Stocks That May Fall Off A Cliff In August - Benzinga